Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis

A Randomised, Double-blind, Placebo-controlled, Event Driven, Phase III Study of Rosuvastatin 20 mg Once Daily in the Long Term Prevention of Recurrent Venous Thromboembolism in Patients With Deep Vein Thrombosis or Pulmonary Embolism

This study evaluates whether treatment with rosuvastatin on top of standard anti-coagulant treatment will decrease the risk of recurrent venous thromboembolism and arterial thromboembolic events in patients with previous deep vein thrombosis or pulmonary embolism.

Inclusion Criteria:

• Signed informed Consent.
• Patients with venous thromboembolism who are treated with anti-coagulant according to the current guidelines

Exclusion Criteria:

• Patients in need of or already treated with lipid lowering drugs
• Active liver or kidney disease or dysfunction or muscle disorders
• Unstable medical or psychological condition that interferes with study participation
• Pregnant woman or woman with childbearing potential who are not willing to use contraception
• History of statin-related muscular pain, or hypersensitivity to statins